Literature DB >> 10458233

Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation.

J E Rubnitz1, B M Camitta, H Mahmoud, S C Raimondi, A J Carroll, M J Borowitz, J J Shuster, M P Link, D J Pullen, J R Downing, F G Behm, C H Pui.   

Abstract

PURPOSE: To determine the molecular characteristics, clinical features, and treatment outcomes of children with acute lymphoblastic leukemia (ALL) and the t(11;19)(q23,p13.3) translocation. PATIENTS AND METHODS: A retrospective analysis of leukemic cell karyotypes obtained from patients with new diagnoses of ALL who were treated at St. Jude Children's Research Hospital or by the Pediatric Oncology Group was performed to identify cases with the t(11;19)(q23;p13.3) translocation. Molecular analyses were performed on these cases to determine the status of the MLL gene and the presence of the MLL-ENL fusion transcript.
RESULTS: Among 3,578 patients with ALL and successful cytogenetic analysis, we identified 35 patients with the t(11;19)(q23;p13.3) translocation: 13 infants and 11 older children had B-precursor leukemia, whereas 11 patients had a T-cell phenotype. Although all of the cases examined had MLL rearrangements and MLL-ENL fusion transcripts, outcome varied according to age and immunophenotype. Among B-precursor cases, only two of the 13 infants remain in complete remission, compared with six of the 11 older children. Most strikingly, no relapses have occurred among B-precursor patients 1 to 9 years of age or among T-cell patients.
CONCLUSION: Although MLL gene rearrangements are generally associated with a dismal outcome in ALL, two distinct subsets with MLL-ENL fusions have an excellent prognosis. Our results suggest that patients with this genetic abnormality who have T-cell ALL or are 1 to 9 years of age should not be considered candidates for hematopoietic stem-cell transplantation during their first remission.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458233     DOI: 10.1200/JCO.1999.17.1.191

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

1.  Secondary acute promyelocytic leukemia in a patient with non-Hodgkin's lymphoma treated with VP-16 and MST-16.

Authors:  Takahiro Okamoto; Masaya Okada; Takeshi Wakae; Ako Mori; Hiroyuki Takatsuka; Eizo Kakishita
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 2.  Chromosomal translocations involving the MLL gene: molecular mechanisms.

Authors:  Peter D Aplan
Journal:  DNA Repair (Amst)       Date:  2006-06-21

Review 3.  The molecular basis of T cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Adolfo Ferrando
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

4.  Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.

Authors:  Juliann Chmielecki; Mark Bailey; Jie He; Julia Elvin; Jo-Anne Vergilio; Shakti Ramkissoon; James Suh; Garrett M Frampton; James X Sun; Samantha Morley; Daniel Spritz; Siraj Ali; Laurie Gay; Rachel L Erlich; Jeffrey S Ross; Joana Buxhaku; Hilary Davies; Vinny Faso; Alexis Germain; Blair Glanville; Vincent A Miller; Philip J Stephens; Katherine A Janeway; John M Maris; Soheil Meshinchi; Trevor J Pugh; Jack F Shern; Doron Lipson
Journal:  Cancer Res       Date:  2017-01-09       Impact factor: 12.701

5.  A case of therapy-related acute lymphoblastic leukemia with t(11;19)(q23;p13.3) and MLL/MLLT1 gene rearrangement.

Authors:  Byong-Joon Yoo; Myung-Hyun Nam; Hwa-Jung Sung; Chae-Seung Lim; Chang-Kyu Lee; Yun-Jung Cho; Kap-No Lee; Soo-Young Yoon
Journal:  Korean J Lab Med       Date:  2011-01

Review 6.  Prognostification of ALL by Cytogenetics.

Authors:  Ansar Hakeem; Aejaz Aziz Shiekh; Gull Mohd Bhat; A R Lone
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-11       Impact factor: 0.900

Review 7.  Gene expression profiling in childhood acute leukemia: progress and perspectives.

Authors:  Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

8.  Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

Authors:  Joanne M Hilden; Patricia A Dinndorf; Sharon O Meerbaum; Harland Sather; Doojduen Villaluna; Nyla A Heerema; Ron McGlennen; Franklin O Smith; William G Woods; Wanda L Salzer; Helen S Johnstone; Zoann Dreyer; Gregory H Reaman
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

9.  Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia.

Authors:  Masafumi Seki; Shunsuke Kimura; Tomoya Isobe; Kenichi Yoshida; Hiroo Ueno; Yaeko Nakajima-Takagi; Changshan Wang; Lin Lin; Ayana Kon; Hiromichi Suzuki; Yusuke Shiozawa; Keisuke Kataoka; Yoichi Fujii; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Teppei Shimamura; Kyoko Masuda; Hiroshi Kawamoto; Kentaro Ohki; Motohiro Kato; Yuki Arakawa; Katsuyoshi Koh; Ryoji Hanada; Hiroshi Moritake; Masaharu Akiyama; Ryoji Kobayashi; Takao Deguchi; Yoshiko Hashii; Toshihiko Imamura; Atsushi Sato; Nobutaka Kiyokawa; Akira Oka; Yasuhide Hayashi; Masatoshi Takagi; Atsushi Manabe; Akira Ohara; Keizo Horibe; Masashi Sanada; Atsushi Iwama; Hiroyuki Mano; Satoru Miyano; Seishi Ogawa; Junko Takita
Journal:  Nat Genet       Date:  2017-07-03       Impact factor: 38.330

10.  Congenital Acute Myeloid Leukemia with Unique Translocation t(11;19)(q23;p13.3).

Authors:  Chester K Yarbrough; S Kathleen Bandt; Kyle Hurth; Jennifer A Wambach; Rakesh Rao; Shashikant Kulkarni; Francis V White; John L Frater; Jeffrey R Leonard
Journal:  Cureus       Date:  2015-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.